TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27116013

Group type: EXPERIMENTAL
Intervention: MLS(®) laser therapy (LT) - 6 sessions, beam area 19.635 cm², 0.168 W/cm², 4 J/cm², starting at fraction 20 of radiotherapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard skin care (Control)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: MLS(®) laser therapy (LT)
Number of subjects: 79
Study: 27116183

Group type: EXPERIMENTAL
Intervention: Foretinib 60 mg po daily
Number of subjects: 45
Study: 27116379

Group type: EXPERIMENTAL
Intervention: Icatibant (self-administered for 62.3% of attacks, healthcare professional-administered for 37.7%)
Number of subjects: 42
Study: 27116910

Group type: EXPERIMENTAL
Intervention: Lorcaserin
Number of subjects: 6136
Study: 27117781

Group type: EXPERIMENTAL
Intervention: African descent (AD)
Number of subjects: 1172

Group type: COMPARATOR
Intervention: European descent (ED)
Number of subjects: 1172
Study: 27117828

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Lower plasma sRAGE levels
Number of subjects: 97

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 97
Study: 27118284

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment (Group 1)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: No treatment (Group 2)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: No treatment (Group 3)
Number of subjects: 1600
Study: 27118452

Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy (first-generation CD19 CAR with CD3ζ endodomain) in NHL1, infused at doses of 25 to 200 × 10(6) cells.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy (second-generation CD19 CAR with CD28 and CD3ζ endodomains) in NHL2, infused at doses of 25 to 200 × 10(6) cells.
Number of subjects: 16
Study: 27118481

Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR)
Number of subjects: 18
Study: 27118540

Group type: EXPERIMENTAL
Intervention: Flavopiridol (30 mg/m² loading dose followed by 30 mg/m² infusion once weekly for 3 weeks every 5 weeks for 2 cycles)
Number of subjects: 10
Study: 27118956

Group type: EXPERIMENTAL
Intervention: Post-discharge transitional care programme (multidisciplinary integrated care team and early review in the clinic)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Post-discharge transitional care programme
Number of subjects: 840

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 840
Study: 27119127

Group type: EXPERIMENTAL
Intervention: Web-based Electronic Self-Report Assessment – Cancer intervention (symptom self-monitoring, tailored education, and communication coaching)
Number of subjects: 663

Group type: COMPARATOR
Intervention: Usual care with symptom self-monitoring alone
Number of subjects: 663
Study: 27120200

Group type: EXPERIMENTAL
Intervention: Type 2C LGMD
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Type 2D LGMD
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Type 2C and 2D LGMD
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline characteristics
Number of subjects: 34
Study: 27121168

Group type: EXPERIMENTAL
Intervention: Neuroischaemic patients (Isc)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Neuropathic patients (Neu)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-diabetic volunteers
Number of subjects: 70
Study: 27121209

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 152
Study: 27121782

Group type: EXPERIMENTAL
Intervention: SB-756050 (various doses)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SB-756050 (two lowest doses)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SB-756050 (two highest doses)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SB-756050 + sitagliptin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg single dose on Day 6)
Number of subjects: 51
Study: 27121890

Group type: EXPERIMENTAL
Intervention: Maternal correlates (age, education, BMI, income, milk feeding practices, ethnicity)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Infant correlates (gender, birth order, infant body size gain)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Maternal correlates
Number of subjects: 1237
Study: 27121948

Group type: EXPERIMENTAL
Intervention: Anti-flagellin IgA in the highest quartile at 6 weeks of age
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Anti-LPS IgA in the highest quartile at 6 weeks of age
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Anti-flagellin IgG in the highest quartile at 6 weeks of age
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Anti-LPS IgG in the highest quartile at 6 weeks of age
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Increased concentrations of anti-flagellin IgA
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Any of the markers (anti-flagellin IgA, anti-LPS IgA, anti-flagellin IgG, anti-LPS IgG)
Number of subjects: 590
Study: 27122492

Group type: EXPERIMENTAL
Intervention: Higher aldosterone levels
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lower aldosterone levels
Number of subjects: 27
Study: 27122675

Group type: EXPERIMENTAL
Intervention: Irinotecan-based chemotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: UGT1A1*28 polymorphism
Number of subjects: 120
Study: 27123488

Group type: EXPERIMENTAL
Intervention: Cervical dystonia patients
Number of subjects: 1000
Study: 27124184

Group type: EXPERIMENTAL
Intervention: Baseline depression
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Baseline depression in normotensive women
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Antidepressant medication usage
Number of subjects: 4680
Study: 27124248

Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limb immobilization
Number of subjects: 0
Study: 27124254

Group type: EXPERIMENTAL
Intervention: Intensive peer coaching and nurse case management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive peer coaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief nurse counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control treatment (including brief peer coaching and brief nurse counseling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All interventions (including control)
Number of subjects: 0
Study: 27124486

Group type: EXPERIMENTAL
Intervention: Dabrafenib (150 mg, twice daily) and trametinib (2 mg/d) continuously until disease progression or intolerance
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib treatment
Number of subjects: 23
Study: 27124715

Group type: EXPERIMENTAL
Intervention: Common single nucleotide polymorphisms (SNPs)
Number of subjects: 1558
Study: 27124835

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg daily for 21 days every 28 days)
Number of subjects: 60
Study: 27125227

Group type: EXPERIMENTAL
Intervention: In vitro fertilization with embryo cryopreservation before live donor uterus transplantation (UTx). Induction immunosuppression. Embryo transfer 12 months after UTx.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Cesarean section performed at 34+6 weeks gestation.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Hysterectomy performed 3.5 months after delivery.
Number of subjects: 1
Study: 27125511

Group type: EXPERIMENTAL
Intervention: FDCA (Fusiform dilatation of the internal carotid artery)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Follow-up after FDCA detection
Number of subjects: 583

Group type: COMPARATOR
Intervention: Survival rates and functional capacity
Number of subjects: 583
Study: 27125892

Group type: EXPERIMENTAL
Intervention: Liletta® 52-mg IUS
Number of subjects: 100
Study: 27126488

Group type: EXPERIMENTAL
Intervention: Lay counsellor clinic linkage facilitation
Number of subjects: 2339

Group type: EXPERIMENTAL
Intervention: Lay counsellor follow-up home visits
Number of subjects: 2339

Group type: COMPARATOR
Intervention: Standard clinic referral
Number of subjects: 2339

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 2339

Group type: EXPERIMENTAL
Intervention: Lay counsellor follow-up visits
Number of subjects: 2339

Group type: COMPARATOR
Intervention: Standard clinic referral for circumcision
Number of subjects: 2339

Group type: EXPERIMENTAL
Intervention: Overall ART initiation
Number of subjects: 2339

Group type: EXPERIMENTAL
Intervention: Linkage to care for HIV-positive participants
Number of subjects: 2339

Group type: EXPERIMENTAL
Intervention: Visit to circumcision facility
Number of subjects: 2339
Study: 27126489

Group type: EXPERIMENTAL
Intervention: HIV status awareness
Number of subjects: 12610

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 12610

Group type: EXPERIMENTAL
Intervention: Viral load measurement
Number of subjects: 12610

Group type: EXPERIMENTAL
Intervention: Virological suppression
Number of subjects: 12610
Study: 27127635

Group type: EXPERIMENTAL
Intervention: STEMI
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: NSTE-ACS
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: NSTE-ACS with prior CVD
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: NSTE-ACS without prior CVD
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: Resource use
Number of subjects: 10568
Study: 27128217

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 0
Study: 27128233

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg, followed by 200 mg QD for days 2-7) plus tofacitinib (30 mg on day 5)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg QD for days 1-3) plus tofacitinib (10 mg on day 3)
Number of subjects: 24
Study: 27128358

Group type: EXPERIMENTAL
Intervention: SIMPLe smartphone application
Number of subjects: 51
Study: 27128614

Group type: EXPERIMENTAL
Intervention: sirolimus (1-4 mg daily oral maintenance doses)
Number of subjects: 24
Study: 27128675

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (days 0-2) plus single dose primaquine (0.75mg/kg on day 2) for P. falciparum infections
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Chloroquine (days 0-2) plus 14 days primaquine (3.5mg/kg total over 14 days) for P. vivax infections
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: G6PD activity measurement
Number of subjects: 181
Study: 27129014

Group type: EXPERIMENTAL
Intervention: Rabeprazole granules
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Rabeprazole granules (to-be-marketed)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Rabeprazole tablets
Number of subjects: 130
Study: 27129117

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg single dose in subjects with mild hepatic impairment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg single dose in subjects with moderate hepatic impairment
Number of subjects: 18
Study: 27129125

Group type: EXPERIMENTAL
Intervention: Tofacitinib 30 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metformin 500 mg
Number of subjects: 24
Study: 27129325

Group type: EXPERIMENTAL
Intervention: Gene therapy (GT) using an autologous CD34(+)-enriched cell fraction transduced with a retroviral vector encoding human ADA cDNA (GSK2696273)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gene therapy (GT)
Number of subjects: 18
Study: 27129602

Group type: EXPERIMENTAL
Intervention: Electronic Activity Monitors (EAM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pedometer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EAM
Number of subjects: 40
Study: 27130216

Group type: EXPERIMENTAL
Intervention: Physician-staffed EMS
Number of subjects: 458

Group type: COMPARATOR
Intervention: Paramedic-staffed EMS
Number of subjects: 458
Study: 27130222

Group type: EXPERIMENTAL
Intervention: i.v. methylprednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: surgical decompression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: blood pressure augmentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: riluzole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: minocycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fibroblast growth factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hypothermia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: glial scar degradation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rho-ROCK inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cell-based therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: novel bioengineered adjuncts
Number of subjects: 0
Study: 27130348

Group type: EXPERIMENTAL
Intervention: RLP cholesterol (RLP-C) levels
Number of subjects: 4932

Group type: EXPERIMENTAL
Intervention: Intermediate-density lipoprotein cholesterol
Number of subjects: 4932
Study: 27130468

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 59
Study: 27130637

Group type: EXPERIMENTAL
Intervention: EMST
Number of subjects: 14
Study: 27132698

Group type: EXPERIMENTAL
Intervention: Idiopathic thrombotic thrombocytopenic purpura (TTP)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Non-idiopathic thrombotic thrombocytopenic purpura (TTP)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Autoimmune disease with anti-ADAMTS13 IgG
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Acquired disease of unknown cause
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Inherited disease (Upshaw-Schulman syndrome)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Obstetrical thrombotic thrombocytopenic purpura
Number of subjects: 939
Study: 27133597

Group type: EXPERIMENTAL
Intervention: Ex vivo expanded CD4(+)CD127(lo/-)CD25(+) regulatory T cells
Number of subjects: 0
Study: 27133664

Group type: EXPERIMENTAL
Intervention: Exenatide (10 mcg b.i.d.)
Number of subjects: 10
Study: 27133759

Group type: EXPERIMENTAL
Intervention: Nintedanib 200mg BID daily in a 4-week cycle until progression or intolerable toxicity
Number of subjects: 24
Study: 27133823

Group type: EXPERIMENTAL
Intervention: Recurrent immunophenotype at diagnosis
Number of subjects: 0
Study: 27134280

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 0
Study: 27135612

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (40 mg/m2 on day 1 and 8) with erlotinib (100 mg daily) in the CSV group (N = 16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (100 mg/week) with erlotinib (100 mg daily) in the MSV group (N = 14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vinorelbine co-administration in the CSV group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vinorelbine co-administration in the MSV group
Number of subjects: 30
Study: 27135792

Group type: EXPERIMENTAL
Intervention: Higher intake of dessert foods
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Higher intake of packaged snack foods
Number of subjects: 146
Study: 27136388

Group type: EXPERIMENTAL
Intervention: Weight loss at the end of the competition
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resting metabolic rate (RMR) at the end of the competition
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Weight regain after 6 years
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: RMR after 6 years
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Metabolic adaptation after 6 years
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Correlation between weight regain and metabolic adaptation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Correlation between weight loss maintenance and metabolic slowing
Number of subjects: 14
Study: 27136905

Group type: EXPERIMENTAL
Intervention: Migalastat HCl 150 mg (single oral dose)
Number of subjects: 32
Study: 27136910

Group type: EXPERIMENTAL
Intervention: Oral canagliflozin 300 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous [(14) C]-canagliflozin 10 µg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Total [(14) C] radioactivity
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Overall assessment
Number of subjects: 9
Study: 27137149

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg once daily on days 1 and 6, twice daily on days 2-5
Number of subjects: 12
Study: 27137427

Group type: EXPERIMENTAL
Intervention: Escitalopram, sertraline, or venlafaxine extended-release, open-label treatment for 8 weeks
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: DTI-derived metric (ratio of fractional anisotropy of the stria terminalis over the CgC)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Escitalopram and sertraline
Number of subjects: 157
Study: 27138005

Group type: EXPERIMENTAL
Intervention: HIV-infected adults
Number of subjects: 500

Group type: COMPARATOR
Intervention: HIV-uninfected controls
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: HIV-infected adults after MMR vaccination
Number of subjects: 500

Group type: COMPARATOR
Intervention: HIV-uninfected controls after MMR vaccination
Number of subjects: 500
Study: 27138015

Group type: EXPERIMENTAL
Intervention: Enobosarm 3 mg orally once daily for 147 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo orally once daily for 147 days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Enobosarm 3 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study: 27138310

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 7835

Group type: EXPERIMENTAL
Intervention: Non-Vitamin K antagonist oral anticoagulants (NOAC)
Number of subjects: 7835

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 7835

Group type: EXPERIMENTAL
Intervention: Rate/rhythm control strategies
Number of subjects: 7835
Study: 27138582

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 2 weeks)
Number of subjects: 32
Study: 27138601

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 7
Study: 27138628

Group type: EXPERIMENTAL
Intervention: Leucine supplementation at varying doses (50 to 750 mg kg(-1) day(-1))
Number of subjects: 6
Study: 27139036

Group type: EXPERIMENTAL
Intervention: Cixutumumab 6 mg/kg q2w
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cixutumumab 10 mg/kg q2w
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cixutumumab 15 mg/kg q3w
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cixutumumab 20 mg/kg q3w
Number of subjects: 21
Study: 27139473

Group type: EXPERIMENTAL
Intervention: β-lactam/β-lactamase inhibitor (BLBLI) combinations in the empirical-therapy cohort (ETC)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Carbapenems in the empirical-therapy cohort (ETC)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: β-lactam/β-lactamase inhibitor (BLBLI) combinations in the targeted-therapy cohort (TTC)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Carbapenems in the targeted-therapy cohort (TTC)
Number of subjects: 627
Study: 27139805

Group type: EXPERIMENTAL
Intervention: Investigational trivalent GBS vaccine (20 μg dose, two injections, 1 month apart)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Investigational trivalent GBS vaccine (0.5 μg, 2.5 μg, or 5.0 μg doses, one injection at 28-35 weeks' gestation)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Investigational trivalent GBS vaccine (various doses)
Number of subjects: 380
Study: 27140229

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily with deleobuvir 800 mg twice daily (b.i.d.) and weight-based ribavirin for 24 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg once daily with deleobuvir 600 mg three times daily (t.i.d.) and weight-based ribavirin for 24 weeks
Number of subjects: 51
Study: 27140401

Group type: EXPERIMENTAL
Intervention: Intravenous iron infusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (iron-replete)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hypoxic exposure (first 6-hour period)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Serum erythropoietin responses to hypoxia
Number of subjects: 13
Study: 27140518

Group type: EXPERIMENTAL
Intervention: Facial VCA procurement
Number of subjects: 35
Study: 27140533

Group type: EXPERIMENTAL
Intervention: Human milk (HM) from obese mothers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Human milk insulin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Human milk leptin and insulin
Number of subjects: 30
Study: 27140803

Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg/day with glyburide 1.25 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/day with metformin 2000 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/day with simvastatin 40 mg/day
Number of subjects: 0
Study: 27141828

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5992

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5992
Study: 27142174

Group type: EXPERIMENTAL
Intervention: Guideline-indicated care (including dietary advice, smoking cessation advice, P2Y12 inhibitors, coronary angiography)
Number of subjects: 389057

Group type: EXPERIMENTAL
Intervention: Missed interventions (coronary angiography, cardiac rehabilitation, smoking cessation advice, statins)
Number of subjects: 389057
Study: 27142184

Group type: EXPERIMENTAL
Intervention: Autofluorescence bronchoscopy (AFB) in addition to low-dose CT (LDCT) scan
Number of subjects: 333

Group type: COMPARATOR
Intervention: Low-dose CT (LDCT) scan
Number of subjects: 333

Group type: COMPARATOR
Intervention: AFB alone
Number of subjects: 333
Study: 27142313

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting regression to normoglycaemia based on non-invasive variables.
Number of subjects: 1197

Group type: EXPERIMENTAL
Intervention: Nomogram model validation.
Number of subjects: 1197